Drugs / SVG103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07287202 | Mar → Dec 2026 expected | hemimegalencephaly, isolated focal cortical dysplasia type II, tuberous sclerosis | Sovargen | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SVG103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07287202 ↗ |
| Route | Oral | “It will be administered once a day (q.d.) orally.” NCT07287202 ↗ |